Results 131 to 140 of about 2,001 (213)

The Reverse Risk Register Approach to Understanding Systemic Factors in Risk Analysis and Management Case Studies

open access: yesRisk Analysis, Volume 46, Issue 9, September 2026.
ABSTRACT Although recent developments have improved clarity on the characteristics of high‐quality risk science, there is recognition that many of those characteristics relate to specific tasks taken by the risk analyst. However, the effectiveness of risk analysis and management often relies on both internal risk team activities and other external ...
Shital Thekdi, Terje Aven
wiley   +1 more source

Surface subgroups for cocompact lattices of isometries of H2n$\mathbb {H}^{2n}$

open access: yesJournal of Topology, Volume 19, Issue 3, September 2026.
Abstract We prove the existence of surface subgroups within any cocompact lattice Γ$\Gamma$ in SO(2n,1)$\mathrm{SO}(2n,1)$ for n⩾2$n\geqslant 2$. This result addresses the cases missing from the work of Hamenstädt in 2015, who constructed surface subgroups in cocompact lattices for all other rank‐1 simple Lie groups of noncompact type.
Jeremy Kahn, Zhenghao Rao
wiley   +1 more source

A preference‐integrated optimization system for medical physics shift scheduling

open access: yesJournal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Background Clinical shift scheduling for medical physicists is challenging given multidisciplinary roles and competing clinical, research, and service demands. Manual workflows often lack the flexibility and transparency needed for this complex field.
Benjamin S. Rosen   +22 more
wiley   +1 more source

Editorial: Culture and emotion in educational dynamics, volume IV. [PDF]

open access: yesFront Psychol
Páez D, da Costa Dutra S, Riquelme EH.
europepmc   +1 more source

Closing the Translational Gap: Closed‐Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics

open access: yesCancer Medicine, Volume 15, Issue 8, August 2026.
Artificial intelligence accelerates cancer therapeutic development through an iterative, closed‐loop pipeline: from AI‐driven target and drug discovery, through automated synthesis and screening, to experimental validation in in vivo tumor models, culminating in clinical translation guided by patient data.
Tuğba Ören Varol, Mehmet Varol
wiley   +1 more source

Home - About - Disclaimer - Privacy